An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

This was the stock's second consecutive day of gains.

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...